Paradigm Biopharmaceuticals PBIGF Stock
Paradigm Biopharmaceuticals Price Chart
Paradigm Biopharmaceuticals PBIGF Financial and Trading Overview
| Paradigm Biopharmaceuticals stock price | 0.13 USD |
| Previous Close | 0.15 USD |
| Open | 0.15 USD |
| Bid | 0.11 USD x 1000000 |
| Ask | 0.17 USD x 1500000 |
| Day's Range | 0.15 - 0.15 USD |
| 52 Week Range | 0.12 - 0.35 USD |
| Volume | 1K USD |
| Avg. Volume | 8.62K USD |
| Market Cap | 78.82M USD |
| Beta (5Y Monthly) | -0.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PBIGF Valuation Measures
| Enterprise Value | 49.92M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 9327.634 |
| Price/Book (mrq) | 14.971196 |
| Enterprise Value/Revenue | 5907.961 |
| Enterprise Value/EBITDA | -1.291 |
Trading Information
Paradigm Biopharmaceuticals Stock Price History
| Beta (5Y Monthly) | -0.02 |
| 52-Week Change | -49.78% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.35 USD |
| 52 Week Low | 0.12 USD |
| 50-Day Moving Average | 0.16 USD |
| 200-Day Moving Average | 0.21 USD |
PBIGF Share Statistics
| Avg. Volume (3 month) | 8.62K USD |
| Avg. Daily Volume (10-Days) | 1.56K USD |
| Shares Outstanding | 525.46M |
| Float | 403.1M |
| Short Ratio | N/A |
| % Held by Insiders | 13.28% |
| % Held by Institutions | 9.01% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | June 30, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | June 30, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -86793.88% |
| Gross Margin | 24.53% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -82.94% |
| Return on Equity (ttm) | -180.21% |
Income Statement
| Revenue (ttm) | 8.45K USD |
| Revenue Per Share (ttm) | 0 USD |
| Quarterly Revenue Growth (yoy) | 50.60% |
| Gross Profit (ttm) | 2.07K USD |
| EBITDA | -38670860 USD |
| Net Income Avi to Common (ttm) | -36091080 USD |
| Diluted EPS (ttm) | -0.07 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 14.74M USD |
| Total Cash Per Share (mrq) | 0.03 USD |
| Total Debt (mrq) | 9.38M USD |
| Total Debt/Equity (mrq) | 156.37 USD |
| Current Ratio (mrq) | 1.305 |
| Book Value Per Share (mrq) | 0.01001924 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -27422296 USD |
| Levered Free Cash Flow (ttm) | -17945332 USD |
Profile of Paradigm Biopharmaceuticals
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | 500 Collins Street |
| ZIP | 3000 |
| Phone | 61 3 9629 5566 |
| Website | https://www.paradigmbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Q&A For Paradigm Biopharmaceuticals Stock
What is a current PBIGF stock price?
Paradigm Biopharmaceuticals PBIGF stock price today per share is 0.13 USD.
How to purchase Paradigm Biopharmaceuticals stock?
You can buy PBIGF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Paradigm Biopharmaceuticals?
The stock symbol or ticker of Paradigm Biopharmaceuticals is PBIGF.
Which industry does the Paradigm Biopharmaceuticals company belong to?
The Paradigm Biopharmaceuticals industry is Biotechnology.
How many shares does Paradigm Biopharmaceuticals have in circulation?
The max supply of Paradigm Biopharmaceuticals shares is 568.84M.
What is Paradigm Biopharmaceuticals Price to Earnings Ratio (PE Ratio)?
Paradigm Biopharmaceuticals PE Ratio is now.
What was Paradigm Biopharmaceuticals earnings per share over the trailing 12 months (TTM)?
Paradigm Biopharmaceuticals EPS is -0.07 USD over the trailing 12 months.
Which sector does the Paradigm Biopharmaceuticals company belong to?
The Paradigm Biopharmaceuticals sector is Healthcare.